Improved efficacy of DMT therapy with SSRIs, Transcend Therapeutics announces the receipt of a $1 million grant with Yale University, Canada approves the first legal medical psilocybin access.
FDA-approval of MDMA therapy on the horizon for 2024, Psilocybin use in naturalistic settings produces lasting results, Psychedelics supported mental health during COVID-19.
Classic psychedelics could help with chronic pain, Clearmind and Johns Hopkins collaborate on psychedelic research, Psychedelic healthcare in Australia held back by lack of safety and efficacy data.
UK MPs welcome psychedelic research, Big pharma backs psychedelic medicine with acquisition, Phase II psilocybin study for major depressive disorder.
Cybin acquires Small Pharma, UK government issues response on psychedelic research, One-third of those under 50 open to psychedelic medicine.
Investors back psychedelic healthcare with US$285 million investment, The use of psychedelic medicines is at a record high, How consciousness may rely on brain cells acting collectively.
World-first study to explore psilocybin for gambling addiction, How psychedelic medicines impact brain oscillations, Psychedelic medicines in the treatment of alcoholism.
How psychedelics could help those living with alcohol use disorders, Psilocybin therapy for anorexia nervosa, Oregon's lucrative psychedelic industry.
Neuroimaging study measures brain activity under psychedelic medicines, Awakn completes the sale of Awakn clinics in Norway, Navigating the industry shakeout.
Psychedelics should be at forefront of EU mental health efforts, urge PAREA, Psilocybin in the treatment of anorexia nervosa, A drug developer's guide to navigating psychedelic trials.
PSYCH Symposium: shifting perceptions, in conversation with Robin Carhart-Harris, The impact of SSRIs on psilocybin-assisted therapy, Psychedelic solutions for police and society.
PSYCH Symposium: exploring psychedelic medicine, Advancing psychedelic healthcare in Europe, Neuroimaging and psychedelic medicine.
Join over 25,000 investors, academics and operators who receive the latest news on the psychedelic science and healthcare industry. Straight to your inbox once a week.